1. Bruttin A, Brussow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother 2005;49(7):2874–8. [
PubMed]
2. Dufour N, Debarbieux L, Fromentin M, Ricard JD. Treatment of highly virulent extraintestinal pathogenic Escherichia coli pneumonia with bacteriophages. Crit Care Med 2015;43(6):190–8. [
PubMed]
3. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage 2011;1(2):66-85. [
PubMed]
4. Renvall S, Niinikoski J, Aho AJ. Wound infections in abdominal surgery. A prospective study on 696 operations. Acta Chir Scand 1980; 146(1):25-30 [
PubMed]
5. Petkovšek Ž, Elersic K, Gubina M, Zgur-Bertok D, Starcic Erjavec M. Virulence potential of Escherichia coli isolates from skin and soft tissue infections. J Clin Microbiol 2009;47(6): 1811-7. [
PubMed]
6. Aghili R, Malek M, Baradaran HR, Peyvandi AA, Ebrahim Valojerdi A, Khamseh ME. General Practitioners' Knowledge and Clinical Practice in Management of People with Type 2 Diabetes in Iran; The Impact of Continuous Medical Education Programs. Arch Iran Med 2015; 18(9):582-5. [
PubMed]
7. Boykoe EJ, Lipsky BA. In: Diabetes in America. Harris MI, editor. Washington DC: National Institutes of Health. Infection and diabetes mellitus; 1995 pp. 485–496.
8. Haghighatpanah M, Mozaffari Nejad AS, Mojtahedi A, Amirmozafari N, Zeighami H. Detection of extended-spectrum β-lactamase (ESBL) and plasmid-borne blaCTX-M and blaTEM genes among clinical strains of Escherichia coli isolated from patients in the north of Iran. J Glob Antimicrob Resist 2016; 7:110-3. [
PubMed]
9. Sulakvelidze A. Bacteriophage therapy. Antimicrob Agents Chemother 2001; 45(3):649-659. [
PubMed]
10. Ackermann HW. Phage Classification and Characterization. Methods Mol Biol 2009;501:127-40. [
PubMed]
11. Ackermann, HW. 5500 Phages examined in the electron microscope. Arch Virol 2007; 152(2):227-243. [
PubMed]
12. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Fifth Informational Supplement. M100-S25. Wayne, Pennsylvania, USA—January 2015
13. Krupovic M, Dutilh BE, Adriaenssens EM, WittmannJ, Vogensen FK, Sullivan MB, et al. Taxonomy of prokaryotic viruses: update from the ICTV bacterial and archaeal viruses subcommittee. Arch Virol 2016;4:1095–9. [
PubMed]
14. Bradley D. Ultrastructure of Bacteriophages and Bacteriocins. Bacteriological Reviews. 1967; 31(4): 230-314. [
PubMed]
15. Ochman H, Selander RK. Standard reference strains of Escherichia coli from natural populations. J Bacteriol 1984;157(2):690-3. [
PubMed]
16. Chain E, Florey HW, Gardner AD, Heatley NG. Penicillin as a chemotherapeutic agent. Lancet 1940; 236(6104):226–8. [
Article]
17. Sulakvelidze A. The challenges of bacteriophage therapy. Eur Ind Pharm 2010;10:14-18. [
Article]
18. Hagens S, Loessner MJ. Application of bacteriophages for detection and control of foodborne pathogens. Appl Microbiol Biotechnol 2007; 76(3):513-9. [
PubMed]
19. Mahony D, Clow J, Atkinson L, Vakharia N, Schlech W. Development and application of a multiple typing system for Clostridium difficile. Appl Environ Microbiol 1991; 57:1873–9. [
PubMed]
20. Slopek S, Durlakowa I, Weber-Dabrowska B, Kucharewicz-Krukowska A, Dabrowski M, Bisikiewicz R. Results of bacteriophage treatment of suppurative bacterial infections. I. General evaluation of the results. Arch Immunol Ther Exp 1983; 31:267–291. [
PubMed]
21. Smith HW, Huggins M. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. Microbiology 1982;128(2):307-318. [
PubMed]
22. Moş I, Micle O, Zdranca M, Muresan M, Vicas L. Antibiotic sensitivity of the Escherichia coli strains isolated from infected skin wounds. Farmacia 2010;58(5):637-644. [
Article]
23. Biswas B, Adhya S,Washart P, Paul B, Trostel AN, Powel B, et al. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun 2002;70(1):204-210. [
PubMed]
، محمد شناگری 
